RELATING TO FOOD AND DRUGS -- UNIFORM CONTROLLED SUBSTANCES ACT
Summary
This bill amends Rhode Island’s Uniform Controlled Substances Act to change how controlled-substance prescriptions are handled, with a specific carve-out for testosterone. The central change is that prescriptions for testosterone may not be transmitted to or reported in the state prescription drug monitoring database, and the Department of Health and Human Services must purge all existing testosterone-related records from that monitoring system. The bill also directs that no future testosterone prescribing or dispensing records be created or maintained in the electronic prescription monitoring program.
Beyond the testosterone provisions, the bill restates and updates a broad set of prescription rules for controlled substances in schedules II through V. It addresses hard-copy and electronic prescribing, facsimile transmission in limited settings, oral prescriptions, partial fills, emergency dispensing, refill limits, recordkeeping, pharmacy reporting, patient counseling on disposal and device use, and required prescriber discussions about opioid risks. It also references federal DEA and Medicare-related electronic prescribing standards and directs the Department of Health to update regulations accordingly.
Impact
The bill would amend § 21-28-3.18 of the General Laws governing controlled-substance prescriptions and pharmacy recordkeeping. Its most direct legal effect is to exempt testosterone from Rhode Island’s prescription drug monitoring database requirements and to require deletion of existing testosterone entries from the controlled-substance monitoring program. It would also preserve and restate the state’s framework for electronic prescribing, pharmacy reporting, and opioid-related counseling, affecting prescribers, pharmacists, pharmacies, and the Department of Health and Human Services.
Sentiment
Based on the bill text and caption, the measure appears aimed at limiting state monitoring of testosterone prescriptions while leaving the broader controlled-substance framework intact. There is no committee transcript or recorded vote history provided, so there is no documented public debate to gauge support or opposition. The overall tone of the bill is regulatory and technical, with a targeted privacy or access-related change for testosterone.
Contention
The main point of contention is likely the testosterone carve-out. Supporters may view the change as reducing unnecessary monitoring or protecting patient privacy, while opponents may argue that removing testosterone from the prescription monitoring database could weaken oversight of controlled substances or create a special exception within the monitoring system. Because no committee discussion or votes are included, specific arguments from legislators, pharmacists, medical providers, or public health advocates are not available in the record provided.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.
Revises sections of the uniform controlled substances act to remove specific opioid dosage requirements, revises the uniform controlled substances act in accordance with current standards of professional practice and would repeal chapter 37.4 of title 5.
Amends current law on controlled substances to permit psilocybin to be cultivated within a person's residence for personal use and contingent on the US FDA's program, mandate that RI department of health establish rules regulations.
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals".
Amends the types of products which pharmacists may prescribe as substitute drugs or products to include "devices and supplies" and "therapeutically equivalent drugs and pharmaceuticals."
Reduces penalties for non-violent drug offenses and provide for terms of imprisonment of not more than 10 years for any drug offense and would repeal certain other offenses.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.